QRG Capital Management Inc. Has $23.94 Million Holdings in Pfizer Inc. $PFE

QRG Capital Management Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 20.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 852,504 shares of the biopharmaceutical company’s stock after acquiring an additional 146,127 shares during the period. QRG Capital Management Inc.’s holdings in Pfizer were worth $23,938,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Horizon Financial Services LLC grew its holdings in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the 4th quarter worth about $26,000. YANKCOM Partnership acquired a new position in Pfizer during the 4th quarter worth about $28,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Abound Financial LLC acquired a new stake in Pfizer in the 4th quarter valued at about $31,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $24.29 on Friday. The company has a market cap of $138.45 billion, a PE ratio of 18.54 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75. The company’s 50-day moving average is $25.63 and its two-hundred day moving average is $26.23.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on PFE shares. UBS Group reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.